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ABSTRACT
Objectives To assess the association between routinely 
prescribed non- steroidal anti- inflammatory drugs 
(NSAIDs) and deaths from COVID-19 using OpenSAFELY, 
a secure analytical platform.
Methods We conducted two cohort studies from 1 
March to 14 June 2020. Working on behalf of National 
Health Service England, we used routine clinical data in 
England linked to death data. In study 1, we identified 
people with an NSAID prescription in the last 3 years 
from the general population. In study 2, we identified 
people with rheumatoid arthritis/osteoarthritis. We 
defined exposure as current NSAID prescription within 
the 4 months before 1 March 2020. We used Cox 
regression to estimate HRs for COVID-19 related death in 
people currently prescribed NSAIDs, compared with those 
not currently prescribed NSAIDs, accounting for age, 
sex, comorbidities, other medications and geographical 
region.
Results In study 1, we included 536 423 current 
NSAID users and 1 927 284 non- users in the general 
population. We observed no evidence of difference 
in risk of COVID-19 related death associated with 
current use (HR 0.96, 95% CI 0.80 to 1.14) in the 
multivariable- adjusted model. In study 2, we included 1 
708 781 people with rheumatoid arthritis/osteoarthritis, 
of whom 175 495 (10%) were current NSAID users. In 
the multivariable- adjusted model, we observed a lower 
risk of COVID-19 related death (HR 0.78, 95% CI 0.64 
to 0.94) associated with current use of NSAID versus 
non- use.
Conclusions We found no evidence of a harmful effect 
of routinely prescribed NSAIDs on COVID-19 related 
deaths. Risks of COVID-19 do not need to influence 
decisions about the routine therapeutic use of NSAIDs.
INTRODUCTION
COVID-19, caused by the SARS- CoV-2, has been 
diagnosed in approximately 18 million patients 
with >690 000 deaths in >200 countries as of 5 
August 2020.1
Key messages
What is already known about this subject?
 ► There have been concerns that non- steroidal 
anti- inflammatory drugs (NSAIDs) may  
increase the risk of COVID-19 disease.  
Recent observational studies reported no 
evidence of a harmful effect of NSAID use on 
COVID-19 severity among patients with  
COVID-19.
 ► However, most studies were of much smaller 
sample size, not general population based 
or did not specifically investigate individual 
NSAIDs (eg, naproxen and ibuprofen).
 ► In addition, limited clinical data are available 
to advise patients using long- term NSAID 
treatment (including people with rheumatoid 
arthritis and osteoarthritis) whether the 
treatment should be continued or stopped in 
the context of COVID-19 pandemic.
What does this study add?
 ► We identified two study populations (2 463 
707 people who ever used NSAIDs in the past 
3 years from the general population and 1 
708 781 people with rheumatoid arthritis/
osteoarthritis) in England using OpenSAFELY 
platform. We then grouped them into current 
users and non- users, respectively, in each study 
population.
 ► In both populations, no association between 
NSAIDs and COVID-19 related death was found.
How might this impact on clinical practice or 
future developments?
 ► This study does not support the hypothesis  
of any harmful effect of NSAIDs on COVID-19 
related deaths among regular NSAID  
users.
 ► Treatment decisions about the routine use of 
NSAIDs do not need to be influenced by fears of 
an effect on COVID-19 outcomes.
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Non- steroidal anti- inflammatory drugs (NSAIDs) are widely 
prescribed for relief of pain and inflammation with nearly 11 
million NSAID prescriptions dispensed in primary care in England 
in the last 12 months.2 Additionally, some NSAIDs (eg, ibuprofen 
and aspirin) are available for sale without a prescription with a 
single brand of ibuprofen alone having sales of approximately 
£100 million per annum.3 Nine non- interventional studies have 
suggested that NSAIDs may be associated with increased risk of 
complications of lower respiratory tract infections4–12; though 
there is evidence that indometacin may have protective antiviral 
effects reported from a single animal study.13
There is now a debate over whether NSAIDs may worsen the 
prognosis of COVID-19. On 14 March, it was recommended 
in France that patients should avoid NSAID use due to an 
apparent worsening of COVID-19 in those taking ibuprofen, 
based on unpublished reports.14 This gained worldwide atten-
tion and resulted in the National Health Service (NHS) England 
medical director issuing a directive that paracetamol should be 
used in preference to NSAIDs14 for symptoms of COVID-19. 
Subsequent reviews by USA, UK and EU drug regulators15–17 
recommended that individuals currently using NSAIDs for the 
management of chronic diseases should continue the treatment 
while calling for more evidence of the impact of NSAIDs in 
patients with COVID-19. Two systematic reviews highlighted a 
lack of studies investigating the effect of NSAIDs on COVID-19, 
demonstrating the urgent need of new studies.18 19 One cohort 
study was recently conducted to investigate such association, but 
individual NSAIDs were not specifically investigated.20
We therefore investigated the association between NSAID use 
and deaths from COVID-19 using linked data from >17 million 
patients in England. We further examined whether the associa-
tion varied by types of NSAID.
METHODS
Study design
We conducted two cohort studies using primary care electronic 
health record data linked to death data from the Office for 
National Statistics between 1 March 2020 and 14 June 2020.
Data source
Primary care records managed by the software provider The 
Phoenix Partnership (TPP) were linked to Office for National 
Statistics death data through OpenSAFELY, a data analytics plat-
form created by our team on behalf of NHS England.21 The 
dataset analysed within OpenSAFELY is based on 24 million 
people currently registered with primary care practices using 
The Phoenix Partnership SystmOne software, representing 40% 
of the English population. It includes pseudonymised data such 
as coded diagnoses, prescribed medications and physiological 
parameters.
Study populations
We identified two cohorts, anticipating that underlying factors 
influencing NSAID use and therefore potential biases would 
differ between them. The first cohort was all people with ≥1 
oral NSAID prescription within the 3 years before study start 
(1 March 2020), identified from the general population. It was 
chosen to minimise confounding by restricting to people who 
were currently prescribed NSAIDs and those who recently 
stopped NSAIDs as their characteristics were likely to be 
more comparable than never- users. The second cohort was all 
people with a diagnosis of rheumatoid arthritis (RA)/osteoar-
thritis (OA) before study start. It was chosen because they were 
potential NSAID users with similar underlying diseases to reduce 
confounding by indication. A patient could be included in both 
cohorts.
In both cohorts, people with missing data for gender, index 
of multiple deprivation, <1 year of primary care records 
or aged <18 or >110 years were excluded. Aspirin is used 
at lower doses as an antiplatelet to prevent cardiovascular 
disease,22 indicating aspirin users constitute a different popu-
lation from other NSAID users. We therefore excluded people 
ever prescribed aspirin in the 10 years before study start or a 
record of either stroke or myocardial infarction before study 
start. We excluded people with a record of gastrointestinal 
bleeding or current asthma before the study start, as they are 
contraindications to NSAIDs.22
Exposures
In the main analysis, we defined current NSAID users as those 
ever prescribed NSAID in the 4 months prior to study start, and 
non- users are those with no record of NSAID prescription in the 
same time period.
We examined whether the association varied by types of 
NSAID, specifically: (1) naproxen dose (categorised as non- 
use, high- dose naproxen (500 mg), low- dose naproxen (250 
mg) and other NSAIDs based on the strength of the formu-
lation), (2) COX-2 specific NSAIDs (categorised as non- 
use, COX-2 specific (celecoxib/etoricoxib) and non- specific 
NSAIDs) and (3) ibuprofen (categorised as non- use, ibuprofen 
and other NSAIDs).
Outcomes
Follow- up for each cohort began on the 1 March 2020 and 
ended either on date of death or study end date (14 June 2020). 
If people in the non- user group received a NSAID prescrip-
tion after 1 March 2020, they were censored at the date of this 
prescription (online supplemental figure S1).
The outcome was COVID-19 related death as registered in 
Office for National Statistics data using International Classifi-
cation of Diseases (ICD)-10 codes U07.1 (‘COVID-19, virus 
identified’) and U07.2 (‘COVID-19, virus not identified’) listed 
either as the underlying or any contributing cause of death. The 
latter ICD-10 code is used when laboratory testing is inconclu-
sive or unavailable.23
Covariates
Figure 1 presents the final list of potential confounders. Our 
methodology for creating codelists for variables has been 
previously described.21 All codelists for identifying exposures, 
covariates and outcomes are openly shared at https:// codelists. 
opensafely. org/.
Statistical methods
Baseline characteristics in each cohort were summarised using 
descriptive statistics, stratified by exposure status. Time to 
COVID-19 related death was displayed in Kaplan- Meier plots. We 
present adjusted cumulative mortality curves and the difference 
between curves using the Royston- Parmar model. We estimated 
HRs with 95% CIs for the association between current NSAID 
use and COVID-19 related death using Cox regression with time 
since cohort entry as the underlying timescale. We accounted 
for competing risk by modelling the cause- specific hazard (ie, 
censoring non- COVID-19 deaths). We used graphical methods 
and tests based on Schoenfeld residuals to explore violations of the 
proportional hazards assumption.









is: first published as 10.1136/annrheum




3Wong AYS, et al. Ann Rheum Dis 2021;0:1–9. doi:10.1136/annrheumdis-2020-219517
Epidemiology
Unadjusted models, models adjusted for age (using restricted 
cubic splines) and sex and multivariable- adjusted models 
including covariates listed in figure 1 were fitted. We strati-
fied the multivariable- adjusted models by geographical regions, 
defined by Sustainability and Transformation Partnerships,24 to 
account for between- region variations. We evaluated the varia-
tion by age (under and 70+ years old) and performed likelihood 
ratio tests to analyse effect modification.
Quantitative bias analysis
We used e- value formulae to calculate the minimum necessary 
strengths of association between an unmeasured confounder 
and exposure or outcome, conditional on measured covariates, 
to fully explain observed non- null adjusted associations (ie, to 
move the observed non- null association to the null).25
Sensitivity analyses
Table 1 shows the list of sensitivity analyses.
Software and reproducibility
Data management was performed using Python V.3.8 and 
SQL, with analysis carried out using Stata V.16.1. All study 
analyses were preplanned unless otherwise stated. All 
code for data management and analyses in addition to the 
Figure 1 Prespecified hypothetical confounders. A&E, accident & emergency; DMARD, disease- modifying antirheumatic drugs; HbA1c, hemoglobin 
A1c; GP, general practice.
Table 1 List of sensitivity analyses
Sensitivity analysis Justification
1. Additionally adjusted for ethnicity in multivariable- adjusted models. In the main analysis, we did not adjust for ethnicity as it was not anticipated to be a strong 
confounder and due to a sizeable proportion of individuals with missing ethnicity (~23%). We 
undertook complete case analysis to address missing data.
2. Additionally adjusted for the number of primary care consultations and A&E 
attendance in the past year in multivariable- adjusted models.
To explore the impact of healthcare- seeking behaviours.
3. For covariate of diabetes severity, we separated people with diabetes 
diagnosis and HbA1c measures ≥58 mmol/mol and those with diabetes 
diagnosis but without HbA1c measures in the past year into two different 
categories.
People with a diabetes diagnosis but not having HbA1c measures in the past year are likely to 
have uncontrolled diabetes due to their potential lack of monitoring and management of diabetes. 
Therefore, we classified these people as uncontrolled diabetes in the main analysis. This is an 
analysis to test the sensitivity of the results.
4. Repeated main analysis with a choice of covariates selected by a DAG 
approach (post hoc analysis).
To test the robustness of the results by choosing a set of covariates that are confounders with the 
use of a structured visual presentation (online supplemental figure S2).
5. Repeated main analysis varying the definition of currently prescribed an 
NSAID to within 2 months of 1 March 2020.
To assess the sensitivity of exposure definition.
6. Repeated main analysis excluding indometacin from all NSAIDs as the 
exposure of interest.
Indometacin was the only NSAID that was suggested to have antiviral activity against SARS 
virus.13
7. Repeated main analysis without censoring people who were prescribed 
NSAIDs after study start date in the non- use group.
To examine data as an intention- to- treat analysis, in order to limit potential bias due to informative 
censoring.
8. Repeated main analysis excluding people ever prescribed aspirin before 
study start date.
To assess the sensitivity of exclusion criteria.
DAG, directed acyclic graph; NSAID, non- steroidal anti- inflammatory drug.
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prespecified protocol are archived at: https:// github. com/ open-
safely/ nsaids- covid- research.
Patient and public involvement
Patients were not formally involved in developing this specific study 
design that was developed rapidly in the context of a global health 
emergency. We have developed a publicly available website https:// 
opensafely. org/ through which we invite any patient or member of 
the public to contact us regarding this study.
RESULTS
Online supplemental figure S3 shows the flow chart of inclu-
sion of participants. A total of 561 027 (13%) individuals were 
included in both study populations. Of them, 175 495 (25%) 
were current NSAID users and 385 532 (11%) were non- users.
MAIN ANALYSIS
Study population 1: general population
Patient characteristics
We included 536 423 current NSAID users and 1 927 284 
non- users (table 2). Median age was 53 years (IQR 42–64) 
among current users and 49 years (IQR 36–60) among non- 
users. More women were current users (59.2%) than non- 
users (56.7%).
Current users were more likely to be obese, former smokers 
and have a medical history of hypertension, diabetes, other 
respiratory diseases, cancer, chronic kidney disease, OA and RA 
than non- users. Current users were also more likely to have a 
prescription for statins, proton pump inhibitors and disease- 
modifying antirheumatic drugs and to have had more primary 
care consultations and vaccinations than non- users.
Unadjusted and multivariable results
Online supplemental figures S4 and S5 present time to 
COVID-19 related death in Kaplan- Meier plots and adjusted 
cumulative mortality plots. We identified 832 COVID-19 related 
deaths in the general population (online supplemental table S1). 
The unadjusted HR for current NSAID use was 1.26 (95% CI 
1.08 to 1.47), compared with non- use in the unadjusted model 
(figure 2). In the multivariable- adjusted model, we observed no 
evidence of difference in risk (HR 0.96, 95% CI 0.80 to 1.14). 
There was no evidence suggesting that the HR differed by age 
in all adjusted models (online supplemental table S2). We did 
not detect deviations from the proportional hazards assumption 
(online supplemental table S3 and figure S6).
Study population 2: RA/OA population
Patient characteristics
We included 175 495 current NSAID users and 1 533 286 non- 
users (table 2). A higher proportion of people aged 70+ years 
were included in this population than the general population. 
Median age was 63 years (IQR 55–71) among current users and 
68 years (IQR 58–76) among non- users. Relative to current 
users, non- users were older at study start date. Approximately 
60% of individuals were women in both groups.
Current users were more likely to be obese, more deprived, 
former/current smokers and to have had more primary care consul-
tations and a prescription for proton- pump inhibitors and disease- 
modifying antirheumatic drugs than non- users. However, non- users 
were more likely to have comorbidities than current users.
Unadjusted and multivariable results
Online supplemental figures S7 and S8 present time to COVID-19 
related death in Kaplan- Meier plots and adjusted cumulative 
mortality curves, respectively. We identified 2573 COVID-19 
related deaths in the RA/OA population (online supplemental table 
S1). The unadjusted HR for current use was 0.43 (95% CI 0.36 
to 0.52), compared with non- use (figure 3). In the multivariable 
model, we observed a lower risk of COVID-19 related death asso-
ciated with current use (HR 0.78, 95% CI 0.64 to 0.94). Post hoc 
analyses, after adjustment for age and sex, showed most variables 
had minimal impact, though adjustment for PPI moved the estimate 
away from the null (online supplemental table S4). There was no 
evidence suggesting that HR differed by age in all adjusted models. 
We did not detect deviations from the proportional hazards assump-
tion (online supplemental table S3 and figure S9).
ANALYSES INVESTIGATING DIFFERENT TYPES OF NSAIDS
Online supplemental tables S5–S10 present the baseline charac-
teristics, stratified by different types of NSAIDs. Online supple-
mental figures S10 and S11 present time to COVID-19 related 
deaths by types of NSAIDs in Kaplan- Meier plots. There was no 
evidence that the association with COVID-19 death varied by: 
(1) naproxen dose, (2) COX- specific status and (3) ibuprofen 
versus other NSAIDs in either study population (figures 2 and 3 
and online supplemental tables S11–S13).
SENSITIVITY ANALYSES
After we excluded people who were ever prescribed aspirin, 
we observed no difference in risk of COVID-19 related death 
associated with current use compared with non- use (HR 0.84, 
95% CI 0.69 to 1.02) in RA/OA population (online supple-
mental table S14). In the post hoc analysis when we used a 
directed acyclic graph (DAG) approach to select covariates, 
we observed a marginal decreased risk of COVID-19 in the 
complete case analysis, additionally adjusted for ethnicity 
(HR 0.79, 95% CI 0.64 to 0.99) (online supplemental table 
S15). The results of all other sensitivity analyses were broadly 
similar to those of the main analyses (online supplemental 
tables S16–S21).
QUANTITATIVE BIAS ANALYSIS
To fully explain the multivariable- adjusted HR (0.78) or the 
upper bound of the 95% CI (0.94) in the RA/OA popula-
tion, an unmeasured confounder would need to be associated 
(conditional on measured covariates) with either non- use, 
relative to current use or COVID-19 mortality by at least risk 
ratio (RR) of 1.88 (effect estimate) or 1.29 (upper bound) and 
with both non- use and COVID-19 mortality by at least RR of 




Based on routinely collected data, our study showed no overall 
increased risk of COVID-19 related death associated with 
current NSAID use in adults, compared with non- use. This was 
consistently seen across all analyses.
In this study, we used two different populations to explore 
the potential impact of confounding. Current users were 
generally older and had more comorbidities than non- users 
in the general population cohort. As expected, this was asso-
ciated with an increased risk of COVID-19 related death 
in current users compared with non- users in the unadjusted 
model. In contrast, current NSAID users were younger 
and had more comorbidities than non- users in the RA/OA 
population, associated with a decreased risk of COVID-19 
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Table 2 Demographic and clinical characteristics
  
Study population 1: general population (people 
prescribed NSAIDs in the past 3 years)
Study population 2: patients with rheumatoid arthritis 
or osteoarthritis
Non- use of NSAIDs Current use of NSAIDS Non- use of NSAIDs Current use of NSAIDS
Total 1 927 284 536 423 1 533 286 175 495
Age as of 1 March 2020
  18–<40 598 513 (31.1) 115 858 (21.6) 32 958 (2.1) 4433 (2.5)
  40–<50 397 201 (20.6) 103 076 (19.2) 97 870 (6.4) 15 813 (9.0)
  50–<60 423 937 (22.0) 133 066 (24.8) 292 186 (19.1) 45 397 (25.9)
  60–<70 283 639 (14.7) 106 205 (19.8) 416 489 (27.2) 56 947 (32.4)
  70–<80 169 281 (8.8) 62 221 (11.6) 436 477 (28.5) 41 350 (23.6)
  80+ 54 713 (2.8) 15 997 (3.0) 257 306 (16.8) 11 555 (6.6)
  Median, IQR 49 (36–60) 53 (42–64) 68 (58–76) 63 (55–71)
Sex
  Female 1 093 581 (56.7) 317 341 (59.2) 951 417 (62.1) 110 526 (63.0)
Body mass index
  <18.5 26 435 (1.4) 6041 (1.1) 19 616 (1.3) 1260 (0.7)
  18.5–24.9 484 862 (25.2) 114 657 (21.4) 379 233 (24.7) 31 531 (18.0)
  25–29.9 577 087 (29.9) 159 573 (29.7) 518 602 (33.8) 55 387 (31.6)
  30–34.9 333 254 (17.3) 106 314 (19.8) 298 505 (19.5) 40 513 (23.1)
  35–39.9 138 059 (7.2) 50 406 (9.4) 119 286 (7.8) 20 062 (11.4)
  40+ 71 503 (3.7) 30 438 (5.7) 58 801 (3.8) 12 396 (7.1)
  Missing 296 084 (15.4) 68 994 (12.9) 139 243 (9.1) 14 346 (8.2)
Ethnicity
  White 1 236 854 (64.2) 357 651 (66.7) 1 095 982 (71.5) 125 073 (71.3)
  Mixed 20 556 (1.1) 4696 (0.9) 6563 (0.4) 830 (0.5)
  Asian/Asian British 151 533 (7.9) 33 010 (6.2) 51 587 (3.4) 6969 (4.0)
  Black 49 618 (2.6) 10 527 (2.0) 17 645 (1.2) 2106 (1.2)
  Other 30 214 (1.6) 6925 (1.3) 10 916 (0.7) 1241 (0.7)
  Missing 438 509 (22.8) 123 614 (23.0) 350 593 (22.9) 39 276 (22.4)
Index of multiple deprivation
  1 (least deprived) 388 369 (20.2) 107 541 (20.0) 313 701 (20.5) 30 797 (17.5)
  2 387 428 (20.1) 108 997 (20.3) 309 372 (20.2) 32 946 (18.8)
  3 382 357 (19.8) 107 626 (20.1) 307 669 (20.1) 34 597 (19.7)
  4 384 598 (20.0) 106 598 (19.9) 303 859 (19.8) 36 682 (20.9)
  5 (most deprived) 384 532 (20.0) 105 661 (19.7) 298 685 (19.5) 40 473 (23.1)
Smoking status
  Never 841 256 (43.6) 220 293 (41.1) 672 833 (43.9) 70 283 (40.0)
  Former 665 068 (34.5) 207 354 (38.7) 692 164 (45.1) 80 983 (46.1)
  Current 389 340 (20.2) 103 258 (19.2) 164 464 (10.7) 23 913 (13.6)
  Missing 31 620 (1.6) 5518 (1.0) 3825 (0.2) 316 (0.2)
Comorbidities
  Hypertension 353 803 (18.4) 128 078 (23.9) 625 247 (40.8) 66 098 (37.7)
  Heart failure 9512 (0.5) 2433 (0.5) 36 888 (2.4) 1413 (0.8)
  Other heart disease 27 881 (1.4) 8726 (1.6) 57 976 (3.8) 4202 (2.4)
  Diabetes
  Controlled
  (HbA1c <58 mmol/mol)
122 653 (6.4) 42 132 (7.9) 177 397 (11.6) 19 535 (11.1)
  Uncontrolled
  (HbA1c ≥58 mmol/mol)
50 268 (2.6) 16 504 (3.1) 58 452 (3.8) 6286 (3.6)
  HbA1c not measured 4536 (0.2) 1303 (0.2) 3695 (0.2) 419 (0.2)
  COPD 42 636 (2.2) 15 435 (2.9) 85 858 (5.6) 8373 (4.8)
  Other respiratory diseases 17 270 (0.9) 6194 (1.2) 38 248 (2.5) 3435 (2.0)
  Cancer 95 315 (4.9) 32 128 (6.0) 174 647 (11.4) 15 940 (9.1)
  Immunosuppression 9285 (0.5) 2918 (0.5) 8498 (0.6) 1009 (0.6)
  Chronic kidney disease 51 642 (2.7) 17 570 (3.3) 164 985 (10.8) 11 148 (6.4)
  Osteoarthritis 367 954 (19.1) 162 676 (30.3) 1 473 833 (96.1) 162 676 (92.7)
  Rheumatoid arthritis 28 690 (1.5) 21 526 (4.0) 95 056 (6.2) 21 526 (12.3)
Primary care consultations
  Median, IQR 5 (2–10) 7 (4–13) 6 (3–11) 8 (5–14)
  Min, Max 0, 626 0, 576 0, 468 0, 360
Continued
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related death in the unadjusted model. Notably, both asso-
ciations were largely removed on adjustment for age. We 
observed a small decreased risk of COVID-19 related death 
among current users in the RA/OA population but not in the 
general population in the multivariable- adjusted models. In 
a post hoc analysis informed by a DAG that captures the 
complexity of relationships between variables, this protec-
tive effect was somewhat attenuated, suggesting it is not a 
robust finding and is subject to model variable selection. 
Moreover, our main analysis in the RA/OA population might 
also be subject to residual confounding. As demonstrated 
in quantitative bias analysis, an unmeasured confounder of 
only moderate strength could potentially fully explain this 
observed association. As we consistently found no evidence 
of harmful effect of NSAIDs on COVID-19 related death, 
using two populations provides a useful context for result 
interpretation.
Findings in context
It was postulated that NSAIDs might delay diagnosis and thus 
clinical care by masking the symptoms of a worsening infec-
tion.4 8–10 26 In vivo and in vitro cellular studies show that 
NSAIDs weaken the immune response to pathogens by limiting 
the local recruitment of innate immune cells and reducing anti-
body synthesis, but the immunomodulatory effects of NSAIDs 
are not fully understood.27 28 Notably, these proposed mech-
anisms are not specific to COVID-19. Recently, it has been 
suggested that ibuprofen upregulates ACE 2,29 which has a role 
in binding SARS- CoV-2 to target cells and could increase the risk 
of developing severe COVID-19 disease through this route.30 
Some animal studies reported that administration of soluble 
recombinant ACE 2 might alleviate lung injury in people with 
respiratory infection.31 32 It remains unknown whether the find-
ings can be generalised to humans.
In line with our results, five observational studies reported 
no evidence of a harmful effect of NSAID use on COVID-19 
  
Study population 1: general population (people 
prescribed NSAIDs in the past 3 years)
Study population 2: patients with rheumatoid arthritis 
or osteoarthritis
Non- use of NSAIDs Current use of NSAIDS Non- use of NSAIDs Current use of NSAIDS
A&E attendance
  Median, IQR 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
  Min, Max 0, 118 0, 152 0, 71 0, 63
Vaccination
  Influenza 435 383 (22.6) 162 082 (30.2) 806 064 (52.6) 86 515 (49.3)
  Pneumococcal 116 464 (6.0) 44 902 (8.4) 193 145 (12.6) 24 744 (14.1)
Medications
  Statin 223 221 (11.6) 87 169 (16.3) 415 120 (27.1) 47 020 (26.8)
  Proton- pump inhibitors 268 934 (14.0) 342 266 (63.8) 371 464 (24.2) 137 180 (78.2)
  Oral prednisolone 39 081 (2.0) 16 084 (3.0) 61 256 (4.0) 8265 (4.7)
  Hydroxychloroquine 8074 (0.4) 6680 (1.2) 16 783 (1.1) 5104 (2.9)
  Other DMARDs 20 770 (1.1) 16 857 (3.1) 48 819 (3.2) 12 753 (7.3)
A&E, accident & emergency; COPD, chronic obstructive pulmonary disease; DMARDs, disease- modifying antirheumatic drugs; HbA1c, hemoglobin A1c; NSAIDs, non- steroidal anti- inflammatory 
drugs.
Table 2 Continued
Figure 2 HRs of the association between current use of NSAIDs 
and COVID-19 related deaths in the general population. NSAIDs, non- 
steroidal anti- inflammatory drugs.
Figure 3 HRs of the association between current use of NSAIDs and 
COVID-19 related deaths in the rheumatoid arthritis or osteoarthritis 
population. NSAIDs, non- steroidal anti- inflammatory drugs.
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severity among patients with COVID-1933–36 but most were 
of much smaller sample size and not all were general popu-
lation based, limiting generalisability.34 A case–control study 
that investigated the association between renin–angiotensin–
aldosterone system blockers and COVID-19 diagnosis found 
no association between NSAIDs and COVID-19 diagnosis.37 
In contrast, a US cohort study reported a lower odds of 
mortality associated with NSAID use prior to hospitalisation 
among patients with COVID-19 (adjusted OR 0.56, 95% CI 
0.40 to 0.82).38 However, patient characteristics, stratified 
by NSAID exposure and the covariates adjusted for, were 
not clear. A recent cohort study demonstrated that NSAIDs 
were not associated with 30- day mortality or other severe 
COVID-19 outcomes in Danish people who tested positive 
for SARS- CoV-2.20 This study was well conducted with robust 
methodology and of large sample size but it might still be 
subject to potential issues around selective testing for COVID-
19. Furthermore, specific types of NSAIDs were not explored 
in the analyses, limiting the interpretation of the results.
Notably, we assessed exposure as NSAID use prior to the 
outbreak in England to establish who were current users, but 
we did not evaluate any potential therapeutic role of NSAIDs 
to treat patients with COVID-19. While our study mainly 
focused on current NSAID use for routine clinical care, there 
are some ongoing clinical trials investigating the role of NSAIDs 
in management of COVID-19. They are due to complete later 
this year or next year (NCT0432563339; NCT0438276840; 
NCT0433462941; and NCT04344457).42
Strengths and limitations
The greatest strength of this study was the power we had to examine 
the association between NSAIDs and COVID-19 death, particularly 
on types of NSAID as our dataset included medical records from 24 
million individuals. We also used two different study populations 
for comparisons to understand the impact of confounding by indi-
cation. The breadth of data available in primary care allows us to 
account for a wide range of potential confounders. We prespecified 
our analysis plan and have openly shared all analytical code.
We recognise possible limitations. First, we do not know whether 
patients truly took the medications as prescribed. Second, the supply 
of NSAIDs ‘over the counter’ is not captured . However, ‘over the 
counter’ purchases are likely to be for ibuprofen, used for acute, 
irregular conditions and may mean some non- users were in fact 
taking ibuprofen. This would tend to bias results towards the null. 
However, this is unlikely to impact the result in the RA/OA popu-
lation as GPs in England prescribe NSAIDs for long- term condi-
tions such as RA/OA.43 In our study, information on indications is 
not readily available; therefore, we cannot distinguish whether the 
NSAID use was for long- term or short- term conditions for further 
investigation. Notably, our results from the RA/OA population can 
generalise the findings to long- term NSAID users as these people 
receive prescriptions regularly to manage their medical condition. 
Additionally, we do not capture all additional medicines commonly 
used in the treatment of RA. In England, a small number of medi-
cines for long- term conditions are supplied routinely by hospitals 
directly to patients.44 This includes biological treatments such 
as adalimumab and infliximab, and we have advocated for the 
release of these data but access remains restricted.45 46 Access to 
these data is important, as biological treatments might be prefer-
entially prescribed in patients with more comorbidities, resulting in 
unmeasured confounding in our RA/OA population. Notably, our 
outcome reflected the probability of both COVID-19 infection and, 
once infected, COVID-19 mortality. If there was a strong harmful 
effect of NSAIDs on either of these endpoints, we would have 
observed a higher hazard of COVID-19 mortality among current 
users compared with non- users. However, we acknowledge that 
behavioural differences between our comparison groups may have 
led to a difference in the risk of infection, for example, if the NSAID 
exposed group were more risk avoidant. This could have attenu-
ated any increased risk of harmful outcomes if differences in risk 
behaviour were substantial.
CONCLUSIONS
We found no evidence of a harmful effect of routinely prescribed 
NSAIDs on COVID-19 related death. People currently prescribed 
NSAIDs for their long- term conditions should continue their 
treatment as part of their routine care.
Information governance
NHS England is the data controller; TPP is the data processor; 
and the key researchers on OpenSAFELY are acting on behalf 
of NHS England. This implementation of OpenSAFELY is 
hosted within the TPP environment, which is accredited to 
the ISO 27001 information security standard and is NHS IG 
Toolkit compliant47 48; patient data have been pseudonymised 
for analysis and linkage using industry standard cryptographic 
hashing techniques; all pseudonymised datasets transmitted for 
linkage onto OpenSAFELY are encrypted; access to the platform 
is via a virtual private network connection, restricted to a small 
group of researchers, their specific machine and IP address; the 
researchers hold contracts with NHS England and only access 
the platform to initiate database queries and statistical models; 
all database activity is logged; only aggregate statistical outputs 
leave the platform environment following best practice for 
anonymisation of results such as statistical disclosure control for 
low cell counts.49 The OpenSAFELY research platform adheres 
to the data protection principles of the UK Data Protection Act 
2018 and the EU General Data Protection Regulation 2016. In 
March 2020, the Secretary of State for Health and Social Care 
used powers under the UK Health Service (Control of Patient 
Information) Regulations 2002 to require organisations to 
process confidential patient information for the purposes of 
protecting public health, providing healthcare services to the 
public and monitoring and managing the COVID-19 outbreak 
and incidents of exposure.50 Taken together, these provide the 
legal bases to link patient datasets on the OpenSAFELY platform. 
General practices (GP), from which the primary care data are 
obtained, are required to share relevant health information to 
support the public health response to the pandemic and have 
been informed of the OpenSAFELY analytics platform.
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